参考资料 [1]Zhu, D., Wang, W., Tong, G.et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun 15, 8408 (202...
[11]. Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides. 2014 Apr;54:19-26. [12]. Burgmaier M, Liberman A, Möllmann ...
▲ 未稀释的 Victoza (6 mg/mL利拉鲁肽)和10倍稀释的Victoza (F10) 的 AF4-UV-MALS 分析。测试了不同的进样量，所有分析均显示UV色谱中的单峰和均匀的~22 kDa的摩尔质量(左)。在色谱图中未观察到其他峰。通过UV的洗脱液中的利拉鲁肽浓度如图所示。"Oligomerization of a Glucagon-like Peptide 1 Analog...
the biological oxygen containing solvents a solvent which is acceptable, there is provided a composition for forming a low viscosity mixture of a GLP-1 analog of at least one d), the pre-formulation is, upon contact with an aqueous fluid, a liquid crystal phase at least one structure a com...
[8] Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:...
[10] Raun, K., von Voss, P., Knudsen, L.B. 2007. Liraglutide, a once-daily human glucagonlike peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 15:1710-1716. [11] Renner, S., Blutke, A., Dobenecker, B., Dhom, G., Muller, T.D.,...
[10] Raun, K., von Voss, P., Knudsen, L.B. 2007. Liraglutide, a once-daily human glucagonlike peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 15:1710-1716. [11] Renner, S., Blutke, A., Dobenecker, B., Dhom, G., Muller, T.D.,...
[41] Muller, T.D., Sullivan, L.M., Habegger, K., Yi, C.X., Kabra, D., Grant, E., et al. 2012. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with Exendin-4 or FGF21. J Pept Sci 18:383-393. ...
[58] Nyholm, B., Orskov, L., Hove, K.Y., Gravholt, C.H., Moller, N., Alberti, K.G., et al. 1999. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941. ...
Eli Lilly, frontrunner in commercializing GLP-1 analogs, eyes obesity treatment market Eli Lilly has long dominated the GLP-1 analog market with its diabetes treatment Trulicity (dulaglutide). The company has also developed Mounjaro (tirzepatide) as the follow-up product of Trulicity. ...